Jonathan is a trial lawyer with over a decade of experience involving intellectual property infringement and validity proceedings. He works regularly with clients in the litigation and pre-litigation context to help them understand and defend their rights, and has represented clients throughout all litigation steps including trials and hearings before the Federal Court and Federal Court of Appeal. His practice encompasses a broad range of commerce, including pharmaceuticals, environmental remediation, medical devices, consumer goods and electrical devices. He has helped clients enforce their intellectual property rights, defend their products and practices from infringement claims, and quantify damages resulting from infringement or lost business opportunities.
Jonathan received a Bachelor of Science in Chemistry from the University of Waterloo and his law degree from Osgoode Hall Law School.
- Successfully represented Pharmascience Inc. at the trial of actions for s. 8 damages involving the drugs pregabalin and zolpidem
- Represented Paid Search Engine Tools in a patent infringement action against Google (2021 FC 1435)
- Successfully represented Teva Canada Limited as Plaintiff in an action for s. 8 damages involving the drug bortezomib, which also involved a counterclaim against Teva for patent infringement (2018 FC 754, 2019 FCA 273)
- Represented Teva Canada Limited as Defendant in an action for quantification of damages following a patent validity action (2016 FC 593, aff’d 2018 FCA 33)
- Represented Suncor Energy Inc. as Defendant in a patent infringement and validity suit involving environmental remediation technology for the oil sands. (Federal Court T-1749-11).
- Represented Mylan Pharmaceuticals in an application under the Patented Medicines (Notice of Compliance) Regulations involving the drug efavirenz (2012 FC 1142)
- Acted for Re:Sound in copyright enforcement actions in the Federal Court of Canada. (T-1162-12; T-1738-12)
- Successfully represented Ratiopharm Inc. in a patent validity action and appeal for the drug Norvasc (2009 FC 711)
- Intellectual Property Institute of Canada
- Canadian Bar Association